Bionano Announces Publication Demonstrating Utility of OGM as an Alternative to KT and CMA for Evaluating CRISPR-Edited Cells as Part of Stem Cell Therapy Development
The study authors found that approximately 15% of CRISPR-Cas9 edited genomes (2 of 13) had potentially pathogenic large chromosomal deletions at unexpected off-target sites. In addition to those two off-target deletions, the authors reported a large, unexpected deletion at the target site.
“This study is an example of how OGM can be used as part of developing cell and gene therapies, including stem cell therapies. The expansion of iPSC-mediated cell therapy faces risks due to off-target structural variations that may be introduced during CRISPR-Cas9 genome editing. Since genome aberrations caused by CRISPR-Cas9 editing could lead to unforeseen adverse effects, we believe careful and comprehensive analysis of edited genomes is important in developing these therapies and their manufacture," commented Erik Holmlin, PhD, president and chief executive officer of Bionano.
The paper is available at: https://www.nature.com/articles/s41467-023-40901-x.
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its
Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “can,” “could,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential utility of OGM in uncovering possible pathogenic structural alterations in CRISPR-Cas9 edited genomes; the utility and ability of OGM to be used as part of developing cell and gene therapies, including stem cell therapies; the importance of comprehensive analysis of edited genomes in order to develop cell and gene therapies, including stem cell therapies, and their manufacture; and our ability to drive adoption of OGM and our technology solutions to be used as part of developing cell and gene therapies including stem cell therapies. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the timing and amount of revenue we are able to recognize in a given fiscal period; the impact of adverse geopolitical and macroeconomic events, such as recent and potential future bank failures, global pandemics and the ongoing conflict between
+1 (858) 888-7610
+1 (858) 888-7625
Source: Bionano Genomics